Abstract As accessibility and legalization of cannabis rise throughout the United States (US), programs have sought guidance about whether its use should be considered a contraindication or, if not a contraindication, what recommendations patients should receive regarding appropriate use before and after metabolic and bariatric surgery (MBS). In this review, medical, nutritional, pharmacological, and psychological considerations are presented by a multidisciplinary group of members of the American Society for Metabolic and Bariatric Surgery (ASMBS). Research suggests several risks associated with long-term cannabis use in the general population, but research in the MBS population, specifically, is limited. Cannabis use is not associated with most postoperative...

Please use this link to access this publication. Abstract There have been recent increases in cannabis use for medical and non-medical (i.e., “recreational”) purposes. One prominent medical use is for cancer-related symptoms. Young adults with a cancer history may have unique cannabis use characteristics, yet little research has examined this topic. This scoping review assessed the literature on cannabis use among young adults with a history of cancer. In October 2024, we conducted a MEDLINE/PubMed search for empirical, peer-reviewed articles written in English. Inclusion criteria were (1) primary research, (2) included participants ages 18–39 previously diagnosed with cancer, (3) included data on cannabis use,...

Abstract Background: There is a need to explore pharmacological options for syndrome (FMS), such as medical cannabis. The aim of this systematic review was to synthesize and analyze the available information about the effectiveness/efficacy and safety of cannabis-based products for medical use (CBPMs) and cannabis-based medicines (CBMs), in patients with FMS. Methods: Interventional or observational studies, systematic reviews and meta-analysis regarding the effectiveness/efficacy and safety of CBPMs and CBMs in patients with FMS were retrieved from the PubMed/Medline database until April 2024. Then, the information was summarized in tables, with the type of CBPM and CBM, the method used in the study and the effective-ness/efficacy and safety outcomes. Results: 19...

Please use this link to access this publication. Abstract The growing use of cannabis for both recreational and medicinal purposes has raised concerns about its cutaneous adverse effects. While systemic implications of cannabis are widely reported, dermatological manifestations remain underrecognized and underreported. This review aims to consolidate existing literature on cannabis-related dermatological complications, including allergic contact dermatitis, urticaria, Stevens-Johnson syndrome (SJS), and cannabis-induced arteritis. Emphasis is placed on mechanisms involving the endocannabinoid system in the skin, case reports of dermatological reactions, and implications for clinical dermatology. A structured methodology was applied to source peer-reviewed articles from databases including PubMed and Scopus, selecting studies published...

Please use this link to access this publication. Abstract Cannabis use represents a significant risk factor for both psychotic disorders and suicidal behaviors, with growing evidence suggesting complex interactions between these variables. This systematic review examines the relationship between cannabis use and suicide risk in first-episode psychosis (FEP) patients, and explores underlying mechanisms, moderating factors, and intervention strategies. Following PRISMA guidelines, we analyzed 50 studies involving 12,764 FEP patients. Results demonstrate that cannabis use, especially high-potency cannabis used regularly, is associated with significantly increased suicide risk with studies consistently reporting elevated odds ratios (ranging from 1.43 to 1.84), and dose-dependent effects—daily use showing higher risk (studies reporting OR: 2.73,...

Abstract The increasing prevalence of cannabis use, with an estimated 219 million users globally, underscores the need to examine its potential health impacts. This review focuses on the arrhythmogenic properties of cannabis, particularly considering its active component, tetrahydrocannabinol, and its interactions with the endocannabinoid system. Epidemiological data and multiple studies indicate a significant association between cannabis use and various arrhythmias, particularly atrial fibrillation. The risk is notably higher among younger users and males. Additionally, case reports have linked cannabis use to other arrhythmias such as ventricular tachycardia and ventricular fibrillation, especially in individuals with underlying cardiac abnormalities. This review also discusses the arrhythmogenic potential...

Please use this link to access this publication. Abstract Cannabis has been consumed for centuries, but global regulatory changes over the past three decades have increased the availability and consumption of cannabis. Cannabinoids are touted to have therapeutic potential for many diseases and could be a replacement for opioids for analgesia and sedation. However, cannabinoids can cause substantial adverse cardiovascular events that would mitigate any potential benefit. The endocannabinoid system regulates mood, satiety and memory, and modulates the cardiovascular system. The link between cannabinoids and cardiovascular disease, which used to be limited to evidence from preclinical studies, case reports and case series, is now...

Abstract This review focuses on Cannabis Hyperemesis Syndrome (CHS) in youth, a condition linked to chronic cannabis use and characterized by cyclic vomiting, abdominal pain, and dehydration. The objectives were to explore CHS progression in youth and its impact on health, and to assess current treatment strategies. There are the three distinct phases of CHS: prodromal, hyperemetic, and recovery. During the prodromal phase, individuals experience early morning nausea and discomfort, often mistakenly alleviated by continued cannabis use. The hyperemetic phase is marked by severe vomiting, dehydration, and complications like electrolyte imbalances, leading to potentially serious health risks. Temporary relief may be experienced through hot...

Abstract Background Increasing legalization of recreational cannabis and availability of cannabinoid products has resulted in expanded use, which is associated with adverse effects including concerns over increased risk of motor vehicle collision (MVC). We aimed to explore the association between cannabis consumption and MVC. Methods We searched MEDLINE, EMBASE, CINAHL, Cochrane library, SCOPUS, PsycInfo, Web of Science, TRID from inception to November 2024. We included studies assessing the association between cannabis consumption on MVC fatalities, any injuries, and culpability/unsafe driving actions. Pairs of reviewers independently screened search results, extracted data, and assessed risk of bias. We used a DerSimonian and Laird random-effects model for...

Abstract Cannabis has a long history as a medicine and was a part of medical practice until the late 19th century. The discovery of cannabidiol (CBD) and ∆9-tetrahydrocannabinol (THC) in the mid-20th century, and then the various components of the endocannabinoid system (ECS) over the following decades has again brought cannabis back into the public eye as a potential therapeutic agent. At present, cannabis is being used in the community across the world for both recreational and medical purposes. In the case of medical usage, it may be prescribed by a medical doctor or purchased either legally or illicitly for medical purposes such as...